Efficacy and Safety of Egg Ladders in Children With IgE-Mediated Hen's Egg Protein Allergy
Launched by MEDICAL UNIVERSITY OF WARSAW · Jun 23, 2025
Trial Information
Current as of July 22, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two different ways of introducing egg into the diets of young children who are allergic to hen’s eggs. The trial compares a 4-step egg ladder and a 5-step egg ladder, which are gradual plans that help children slowly and safely get used to eating eggs again. The goal is to see which method is more effective and safe for helping kids build tolerance to eggs over time.
Children between 1 and 5 years old who have a confirmed allergy to hen’s eggs and have been avoiding eggs for at least six months may be eligible. To join, children need to be generally healthy and have a clear diagnosis of egg allergy, confirmed by specific allergy tests or a controlled food challenge. Families will be asked to follow the assigned egg ladder plan and work closely with the study team. The study will monitor how well the children tolerate the egg introduction and watch for any allergic reactions. This research is important because it could help standardize the best way to safely reintroduce eggs to allergic children, improving their quality of life.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 12 months and ≤ 5 years.
- • Diagnosis of IgE-mediated HEA confirmed according to the EAACI guidelines by a positive OFC with hen's egg proteins. In children with high-risk HEA (e.g., history of anaphylaxis), diagnosis can be based on elevated specific IgE levels (3.5 kU/l) to hen's egg proteins and/or individual egg components and/or positive skin tests.
- • On a therapeutic elimination diet for at least 6 months, measured from the last allergic reaction to egg (in accordance with BSACI guidelines).
- • Eligible regardless of the risk of systemic reactions (e.g. anaphylaxis) or asthma.
- • Good general health.
- • Written informed consent signed by the child's guardians.
- • Demonstrated good cooperation from the patient's guardians.
- Exclusion Criteria:
- • Confirmed wheat allergy and/or celiac disease.
- • Uncontrolled asthma, defined as the presence of shortness of breath, cough, chest tightness, or auscultatory changes despite treatment.
- • Signs of exacerbation of a chronic disease.
- • Signs of acute infectious disease (e.g. acute rhinitis, cough, subfebrile or febrile states).
- • Signs of exacerbation of another allergic disease (e.g., conjunctivitis, allergic rhinitis, atopic dermatitis).
- • Anaphylaxis due to hen's egg proteins within the last 6 months.
- • Use of antihistamines within 3-10 days before the challenge (depending on the drug and indication; time-limited contradiction - relative exclusion criterion).
- • Acquired tolerance to baked hen's egg proteins or advancement to a higher step of the egg ladder.
- • Use of immunosuppressive drugs or immunotherapy.
About Medical University Of Warsaw
The Medical University of Warsaw is a leading academic institution dedicated to advancing healthcare through innovative research and education. Renowned for its commitment to excellence in medical training and clinical practice, the university actively engages in a diverse range of clinical trials aimed at improving patient outcomes and enhancing medical knowledge. With a robust infrastructure and a multidisciplinary team of experts, the Medical University of Warsaw fosters collaboration in the development of novel therapies and interventions, contributing significantly to the global medical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Warsaw, , Poland
Warsaw, , Poland
Patients applied
Trial Officials
Hanna Szajewska, MD, Professor
Principal Investigator
Medical University of Warsaw
Anna Nowak-Węgrzyn, MD, Professor
Principal Investigator
Collegium Medicum, University of Warmia and Mazury, Olsztyn, Poland; New York Univeristy, Grossmann School of Medicine
Andrea Horvath, MD, PhD
Principal Investigator
Medical Univeristy of Warsaw
Joanna Jerzyńska, MD, PhD
Principal Investigator
Medical Univeristy of Lodz
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported